The Journal of Rheumatology

Volume 36: No. 4

April 2009

Editorials

Anti-Cyclic Citrullinated Peptide in Preclinical Rheumatoid Arthritis: Food for Thought
H.A. Ménard .......................................................... 663

Pulmonary Arterial Hypertension in Systemic Sclerosis: Can We Predict Responders for Successful Therapy?
A.A. Sasahara ......................................................... 665

Should Rheumatologists Retain Ownership of Fibromyalgia?
Y. Shir, M.A. Fitzcharles ........................................... 667

Reviews

Fibromyalgia Wars F. Wolfe ....................................... 671

Explaining Medically Unexplained Symptoms: Widespread Pain H.A. Smythe ......................................... 679

Articles

IL-17 Increases the Expression of TLR-2, 4, and 9 by Increasing IL-1β and IL-6 Production in Autoimmune Arthritis

Association of Polymorphisms in IRF5 Gene with RA: A Metaanalysis S.W. Han, W.K. Lee, K.T. Kwon, B.K. Lee, E.J. Nam, G.W. Kim ................................................................. 693

Hypoxia-induced Abrogation of Contact-dependent Inhibition of RA Synovial Fibroblast Proliferation
Y. Nonomura, F. Mizoguchi, A. Suzuki, et al .......................... 698

Comparison of Threshold Cutpoints and Continuous Measures of Anti-CCP Antibodies in Predicting Future RA

Anti-CCP Antibodies Distinguish HBV-associated Arthropathy from Concomitant RA in Patients with Chronic HBV Infection

Implementation of Z-Scores as an Age- and Sex-independent Parameter for Estimating Joint Space Widths in RA

Circulating Leptin and Adiponectin Concentrations During TNF Blockade in Patients with Active RA
C. Pope, M.G. Netea, J. de Graaf, et al ............................. 724

MBL Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-CCP-Positive Patients with Early RA

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with RA Receiving Background MTX: A 5-year Extended Phase IIIB Study
R. Westhovens, J.M. Kremer, L.W. Moreland, et al .......................... 736

Hidden Cost of RA: Estimating Cost of Comorbid Cardiovascular Disease and Depression Among Patients with RA
A.T. Joyce, P. Smith, R. Khandker, J.M. Melin, A. Singh ................................................................. 743

Autoantibodies to TNF in Patients with RA and SLE
B.J. Rosenau, P.H. Schur ................................................. 753

Serum Levels of Ficolin-3 (Hakata Antigen) in Patients with SLE
T. Andersen, L. Munthe-Fog, P. Garred, S. Jacobsen .................................................. 757

Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to CTD
G. Cella, F. Vianello, F. Cozzi, et al ........................................ 760

Quality of Life in Patients with SSc Compared to the General Population and Patients with Other Chronic Conditions
M. Hudson, B.D. Thombs, R. Steele, P. Panopalis, E. Newton, M. Baron, for the Canadian Scleroderma Research Group .................................. 768

Surfactant Protein D and KL-6 as Serum Biomarkers of ILD in Patients with Scleroderma
F.N. Hant, A. Ludwicka-Bradley, H-J. Wang, et al, for the Scleroderma Lung Study Research Group ........................................ 773

CENP-O, a Protein Localized at the Centromere Throughout the Cell Cycle, Is a Novel Target Antigen in SSc
A. Saito, Y. Muro, K. Sugiuira, M. Ikeno, K. Yoda, Y. Tomita ................................................................. 781

Ethnic Influence on Disease Manifestations and Autoantibodies in Chinese-Descent Patients with SSc
A.H.L. Low, S.R. Johnson, P. Lee ...................................... 787

Rate of Discordant Findings in Bilateral Temporal Artery Biopsy to Diagnose GCA
G.S. Breuer, G. Neshar, R. Neshar ....................................... 794

The Immune Response to Autologous Bacteroides in AS Is Characterized by Reduced IL-10 Production
S.M. Stebbings, C. Taylor, G.W. Tannock, M.A. Baird, J. Highton ................................................................. 797

Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active AS
M. Rudwaleit, P. Claudepierre, P. Wordsworth, et al .......................... 801

Prevalence of Hip Symptoms and Radiographic and Symptomatic Hip OA in African Americans and Caucasians: The Johnston County Osteoarthritis Project